CAMP4 Therapeutics Corporation (CAMP) AI Stock Analysis

• Market Cap: $321.66M
• Dividend Yield: N/A
• Average Volume (3M): 1.59M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.94
• Revenue Growth: N/A
• EPS Growth: 5.51%
• Country: US
• Employees: 55
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.55
• Shares Outstanding: 51,881,134
• 10 Day Avg. Volume: 141,089
• 30 Day Avg. Volume: 1,592,597
• PEG Ratio: 0.06
• Price to Book (P/B): 1.61
• Price to Sales (P/S): 156.16
• P/FCF Ratio: -2.21
• Enterprise Value/Market Cap: -0.03
• Enterprise Value/Revenue: -2.22
• Enterprise Value/Gross Profit: -2.49
• Enterprise Value/Ebitda: 0.16
• 1Y Price Target: $9.00
• Price Target Upside: 45.16% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 49 Neutral
• Price Target: $6.00 ▼(-3.23% Downside)

The score is held back primarily by weak financial performance (losses, cash burn, and leverage risk). Technical momentum is constructive and recent corporate events—especially the GSK collaboration and program advancement—are positives, but valuation support is limited given negative earnings.

Positive Factors

Strategic Partnership

The collaboration with GSK provides CAMP4 with an upfront payment and potential milestone payments, enhancing financial stability and leveraging GSK's commercialization capabilities, which can accelerate product development and market entry.

Facility Expansion

Expanding to a larger facility in Watertown supports CAMP4's operational growth and positions it in a key biotech hub, potentially improving research capabilities and attracting talent, which is crucial for long-term innovation and development.

Pipeline Advancement

Initiating GLP toxicology studies for CMP-SYNGAP-01 marks progress towards clinical trials, advancing CAMP4's pipeline and addressing unmet medical needs, which can enhance its market position and future revenue potential.

Negative Factors

High Leverage

High leverage indicates financial risk, as excessive reliance on debt can strain cash flow and limit flexibility, potentially impacting CAMP4's ability to invest in growth and weather economic downturns.

Negative Cash Flow

Negative cash flow suggests inefficiencies in operations and financial management, raising concerns about CAMP4's liquidity and ability to sustain operations without external financing, which could hinder long-term growth.

Volatile Revenue

Volatile revenue and declining profit margins indicate instability in CAMP4's business model, potentially affecting its ability to maintain consistent growth and profitability, which is critical for investor confidence and strategic planning.

CAMP4 Therapeutics Corporation Business Overview & Revenue Model

Company Description

CAMP4 Therapeutics Corp. operates as a biotechnology company which engages in the discovery of treatment options for patients. The company was founded by Richard A. Young and Leonard Zon in 2015 and is headquartered in Cambridge, MA.

How the Company Makes Money

CAMP4 Therapeutics primarily generates revenue through several key streams, including research collaborations, licensing agreements, and potential milestone payments from partnerships with larger pharmaceutical companies. The company often enters into strategic partnerships to co-develop its therapeutic candidates, which can provide upfront payments and ongoing funding for research and development. Additionally, CAMP may receive royalties on sales of products developed from its proprietary technologies. The success of its revenue model is significantly bolstered by the strong demand for innovative treatments in the biotechnology sector and the increasing interest from investors and partners in RNA-based therapies.

CAMP4 Therapeutics Corporation Financial Statement Overview

Summary

Weak overall fundamentals: volatile and declining revenues, negative EBIT/EBITDA margins, high leverage (very elevated debt-to-equity in 2023), and negative operating/free cash flow raise liquidity and financial stability concerns despite a high gross margin.

Income Statement

CAMP4 Therapeutics Corporation has shown significant volatility in its revenue and profit margins. The company experienced a dramatic revenue decline from 2020 to 2024, with a notable drop in net profit margins, indicating challenges in maintaining profitability. The gross profit margin remains high, but negative EBIT and EBITDA margins highlight operational inefficiencies. The revenue growth rate is erratic, with periods of decline, suggesting instability in revenue streams.

Balance Sheet

The balance sheet reveals a concerning financial structure with fluctuating debt-to-equity ratios, reaching as high as 16.81 in 2023, indicating high leverage. The negative return on equity suggests that the company is not generating sufficient returns on shareholders' investments. The equity ratio is low, reflecting a reliance on debt financing, which could pose risks if not managed properly.

Cash Flow

CAMP4 Therapeutics Corporation's cash flow statement indicates negative operating and free cash flows, with inconsistent free cash flow growth. The operating cash flow to net income ratio is negative, suggesting inefficiencies in converting income into cash. The free cash flow to net income ratio is slightly positive, but overall cash flow management appears weak, raising concerns about liquidity and financial flexibility.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	3.80M	652.00K	350.00K	0.00	295.84M	308.59M
Gross Profit	3.39M	652.00K	350.00K	0.00	121.89M	122.41M
EBITDA	-53.58M	-51.39M	-50.20M	-44.12M	7.49M	18.13M
Net Income	-53.40M	-51.79M	-49.29M	-44.19M	-31.15M	-21.16M
Balance Sheet
Total Assets	86.39M	78.31M	54.95M	102.55M	402.29M	441.82M
Cash, Cash Equivalents and Short-Term Investments	75.25M	64.04M	38.38M	83.19M	91.11M	91.69M
Total Debt	6.35M	8.65M	11.69M	12.39M	209.17M	210.80M
Total Liabilities	27.73M	15.16M	178.68M	180.08M	322.11M	342.50M
Stockholders Equity	58.67M	63.14M	-123.73M	-77.53M	80.18M	99.32M
Cash Flow
Free Cash Flow	-47.68M	-46.00M	-44.83M	-42.57M	-17.52M	17.23M
Operating Cash Flow	-47.13M	-45.56M	-44.16M	-38.54M	-4.22M	28.59M
Investing Cash Flow	-785.00K	-441.00K	-678.00K	-4.03M	-7.58M	-13.69M
Financing Cash Flow	120.37M	71.66M	301.00K	100.16M	-2.64M	-27.32M

CAMP4 Therapeutics Corporation Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 6.20
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CAMP, the sentiment is Positive. The current price of 6.2 is above the 20-day moving average (MA) of 6.20, above the 50-day MA of 4.77, and above the 200-day MA of 2.84, indicating a bullish trend. The MACD of 0.41 indicates Positive momentum. The RSI at 62.29 is Neutral, neither overbought nor oversold. The STOCH value of 62.96 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CAMP.

CAMP4 Therapeutics Corporation Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ARTV	58 Neutral	$112.91M	-1.41	-47.96%	―	-100.00%	-17.10%
RLMD	57 Neutral	$316.80M	-2.47	-196.79%	―	―	37.37%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CAMP	49 Neutral	$321.66M	-2.53	-172.70%	―	―	5.51%
INKT	48 Neutral	$59.22M	-4.09	―	―	―	21.48%
BYSI	43 Neutral	$62.92M	―	―	―	―	―
OSTX	41 Neutral	$53.88M	-1.89	-914.04%	―	―	-133.00%

CAMP4 Therapeutics Corporation Corporate Events

CAMP4 Therapeutics Restructures Leases and Expands Facilities

On December 22, 2025, CAMP4 Therapeutics Corporation amended its existing lease for approximately 30,760 square feet of laboratory and office space at One Kendall Square in Cambridge, Massachusetts, accelerating the termination of that lease to 30 days after the commencement of a new lease in Watertown, while securing an abatement of base rent at the Cambridge site from October 1, 2025 until the early termination date, contingent on remaining in compliance with both leases. On the same date, the company signed a new lease for about 44,000 square feet of laboratory and office space at 100 Talcott Avenue in Watertown, Massachusetts, running through June 30, 2030, with base rent starting at $40 per square foot and increasing annually, and agreed to pay a $2.1 million lease modification fee in exchange for additional rent abatement at the new site, a move that expands its footprint and restructures its real estate costs in a key biotech hub.

The most recent analyst rating on (CAMP) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on CAMP4 Therapeutics Corporation stock, see the CAMP Stock Forecast page.

CAMP4 Therapeutics Announces $28 Million Common Stock Offering

On December 18, 2025, CAMP4 Therapeutics Corporation entered into an underwriting agreement with Leerink Partners LLC to offer 5,000,000 shares of its common stock at $6.00 per share, all sold by the company, with expected net proceeds of approximately $28 million and an anticipated closing on or about December 19, 2025, subject to customary conditions. The deal includes standard underwriting terms such as indemnification provisions and a 60-day lock-up restricting share sales by the company, executives, directors and certain stockholders, while allowing sales under its at-the-market program after 30 days, underscoring CAMP4’s continued reliance on equity financing to support its business and potentially affecting share liquidity and ownership dynamics in the near term.

The most recent analyst rating on (CAMP) stock is a Hold with a $6.00 price target. To see the full list of analyst forecasts on CAMP4 Therapeutics Corporation stock, see the CAMP Stock Forecast page.

CAMP4, GSK form RNA therapeutics collaboration agreement

On December 17, 2025, CAMP4 Therapeutics entered into a strategic research, collaboration and license agreement with GSK to discover and develop antisense oligonucleotide therapeutics targeting regulatory RNAs linked to multiple neurodegenerative and kidney disease gene targets, combining CAMP4’s regRNA mapping and RAP Platform-based ASO discovery capabilities with GSK’s global development and commercialization infrastructure. Under the deal, CAMP4 granted GSK an exclusive worldwide license to develop and commercialize resulting compounds and products, will conduct early research to deliver lead ASO series before GSK assumes full responsibility for clinical development, regulatory work, manufacturing and commercialization, and will receive a $17.5 million upfront payment plus eligibility for up to $440 million in development and commercial milestones and tiered royalties, positioning CAMP4 to monetize its RNA platform while potentially expanding its presence in neurodegenerative and renal disease markets without bearing late-stage development risk.

The most recent analyst rating on (CAMP) stock is a Hold with a $6.00 price target. To see the full list of analyst forecasts on CAMP4 Therapeutics Corporation stock, see the CAMP Stock Forecast page.

CAMP4 Initiates GLP Toxicology Studies for CMP-SYNGAP-01

On October 1, 2025, CAMP4 Therapeutics announced the initiation of GLP toxicology studies for its lead product candidate, CMP-SYNGAP-01, aimed at treating SYNGAP1-related disorders. The studies are a crucial step toward a clinical trial application, potentially leading to a Phase 1/2 clinical trial by the second half of 2026. SYNGAP1-related disorders, which significantly impact cognitive development, currently lack FDA-approved therapies, highlighting the potential impact of CAMP4’s innovative approach on the treatment landscape.

The most recent analyst rating on (CAMP) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on CAMP4 Therapeutics Corporation stock, see the CAMP Stock Forecast page.